论文部分内容阅读
目的:探讨Hyper-CVAD/MA方案治疗复发或难治弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)的疗效及安全性。方法:观察26例经系统化疗后复发或难治的DLBCL患者接受Hyper-CVAD/MA方案化疗,21-28天为1周期,连续2个周期评价疗效及安全性,分析生存情况。结果:全组26例患者中,总有效率为46.15%,其中完全缓解(complete remission,CR)3例(11.54%),部分缓解(partial remission,PR)9例(34.61%),全组患者中位生存时间为10(2-25)个月,1年和2年总生存率分别为28.57%、14.29%。不良反应主要表现为III-IV度骨髓抑制及继发的肺部感染,其他包括胃肠道反应、口腔炎、肝功能异常等。结论:Hyper-CVAD/MA治疗复发难治DLBCL有一定的疗效,且患者可耐受,可作为二线方案的一个选择。
Objective: To investigate the efficacy and safety of Hyper-CVAD / MA in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Methods: Twenty-six patients with DLBCL relapsed or refractory to systemic chemotherapy undergoing chemotherapy with Hyper-CVAD / MA regimen were enrolled. One cycle of 21-28 days was performed. The efficacy and safety of two cycles were evaluated and the survival was analyzed. Results: Of the 26 patients, the total effective rate was 46.15%. Among them, 3 patients (11.54%) had complete remission (CR), 9 patients (34.61%) had partial remission (PR), all patients The median survival time was 10 (2-25) months. The 1-year and 2-year overall survival rates were 28.57% and 14.29%, respectively. Adverse reactions mainly manifested as III-IV degrees of myelosuppression and secondary pulmonary infection, other including gastrointestinal reactions, stomatitis, liver dysfunction. Conclusion: Hyper-CVAD / MA treatment of refractory DLBCL recurrence has a certain effect, and patients can be tolerated, as a second-line options as an option.